Evidence map›Paper›PMID 32299860›Full record

Trial reportThe European respiratory journal2020

The effect of exacerbation history on outcomes in the IMPACT trial.

David M G Halpin, Mark T Dransfield, MeiLan K Han, C Elaine Jones, Sally Kilbride, Peter Lange, David A Lipson, David A Lomas, Fernando J Martinez, Steve Pascoe and 3 more

Erratum issuedOpen access · hybridAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The European respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Burden of Exacerbations in Patients Newly Initiating an Inhaled Regimen for COPD: A Claims Analysis.International journal of chronic obstructive pulmonary disease · 2025
    Article
  7. Quality of Care and Outcomes of Inpatients with COPD: A Multi-Center Study in China.International journal of chronic obstructive pulmonary disease · 2025
    Observational
  8. Review
  9. Observational
  10. Article
  11. Review
  12. How inhaled corticosteroids target inflammation in COPD.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  13. Rational use of inhaled corticosteroids for the treatment of COPD.NPJ primary care respiratory medicine · 2023
    Review
  14. Review
  15. Towards precision in defining COPD exacerbations.Breathe (Sheffield, England) · 2021
    Review
  16. Current developments and future directions in COPD.European respiratory review : an official journal of the European Respiratory Society · 2020
    Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 13 institutions in 3 countries.

David M G HalpinUniversity of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK d.halpin@nhs.net.
Mark T DransfieldDivision of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA.
MeiLan K HanUniversity of Michigan, Pulmonary & Critical Care, Ann Arbor, MI, USA.
C Elaine JonesGlaxoSmithKline, Research Triangle Park, NC, USA.
Sally KilbrideGlaxoSmithKline, Stockley Park, UK.
Peter LangeMedical Dept, Herlev and Gentofte Hospital, Herlev, Denmark.
David A LipsonGlaxoSmithKline, Collegeville, PA, USA.ORCID 0000-0001-6732-4593
David A LomasUCL Respiratory, University College London, London, UK.
Fernando J MartinezNew York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA.
Steve PascoeGlaxoSmithKline, Collegeville, PA, USA.
Dave SinghUniversity of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Hospitals Trust, Manchester, UK.
Robert WiseDivision of Pulmonary and Critical Care Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.ORCID 0000-0002-8353-2349
Gerard J CrinerLewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
GlaxoSmithKline (United Kingdom) · GBGlaxoSmithKline (United States) · USJohns Hopkins University · USNewYork–Presbyterian Hospital · USResearch Triangle Park Foundation · USSanofi (United States) · USTemple University · USUniversity College London · GBUniversity of Alabama at Birmingham · USUniversity of Copenhagen · DKUniversity of Exeter · GBUniversity of Manchester · GBUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IMPACT, a 52-week, randomised, double-blind trial, assessed the efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy

Indexed as

Administration, InhalationAdrenergic beta-2 Receptor AgonistsAgedAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDisease ProgressionDouble-Blind MethodDrug CombinationsFemaleHealth StatusHumansLungMaleMiddle AgedAdrenergic beta-2 Receptor AgonistsAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug Combinationsfluticasone furoateGSK573719Muscarinic AntagonistsQuinuclidinesvilanterol

Identifiers

PMID32299860
PMCPMC7286387
OpenAlexW3017334480

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.